Autonomix Medical (AMIX) Projected to Post Earnings on Wednesday

Autonomix Medical (NASDAQ:AMIX) is anticipated to release its Q2 2027 resultson Wednesday, November 11th. Analysts expect Autonomix Medical to post earnings of ($2.62) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Autonomix Medical (NASDAQ:AMIX) last issued its earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, beating the consensus estimate of ($6.40) by $1.38. On average, analysts expect Autonomix Medical to post ($20.17) EPS for the current fiscal year and ($17.44) EPS for the next fiscal year.

Autonomix Medical Price Performance

Shares of Autonomix Medical stock traded up $0.07 on Wednesday, hitting $1.73. 9,644 shares of the company’s stock traded hands, compared to its average volume of 1,388,906. The firm’s 50-day moving average price is $3.68 and its two-hundred day moving average price is $6.73. The stock has a market capitalization of $1.67 million, a PE ratio of -0.04 and a beta of -0.70. Autonomix Medical has a one year low of $1.63 and a one year high of $32.55.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMIX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Autonomix Medical in a research note on Monday, October 26th. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Autonomix Medical currently has a consensus rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.